activity have subsided as a result of administrating a gluten-free diet.
Material and Methods
This prospective study was approved by the Kermanshah University of Medical Sciences (KUMS) ethics committee and was conducted from April 2012 to February 2014. Epileptic patients who were referred to the neurology clinic at Imam Reza and Farabi hospitals, Kermanshah, were recruited to participate in this study. All participants provided written informed consent in compliance with the KUMS review board.
The definitions of seizure type and epilepsy syndrome were as per the International League Against Epilepsy (ILAE) that was proposed by Nordli (2005) [9] . Patients with acute and remote symptomatic seizures, evidence of abnormality in neuroimaging as the cause of seizures, neurodegenerative or metabolic disorders with epilepsy, non-epileptic attack disorders, patients with symptomatic epilepsy due to brain damage, cerebral malformation, metabolic disorders, degenerative diseases, tumors, and hemorrhage were not included in the study. All patients were asymptomatic from gastrointestinal disturbances.
Measuring immunoglobulin A antiendomysial antibodies by indirect immunofluorescence was used to screen for CD. In the patients testing positive for IgA antibodies, 2-3 endoscopic small bowel biopsies were taken from the distal duodenum. CD has been simplified and was based on the demonstration of immunoglobulin A antiendomysial antibodies and an intestinal biopsy showing pathologic changes typical of CD.
Following the diagnosis of CD, the patients began a strict gluten-free diet for five months, while the antiepileptic treatment was maintained. About 3 months after commencing the gluten-free diet, intestinal biopsies were repeated and improved intestinal pathological changes were recorded to determine the patient's response to treatment. The diagnosis was confirmed when the antiendomysial antibodies disappeared during the gluten-free diet. The patient's seizure activity was recorded during the course of five months.
Statistical Analysis
Data is presented as mean ± SD or frequency and percent, using descriptive statistics. To compare the difference in the IgA levels of CD-positive and -negative cases Student's t-test was used. A value of p < 0.05 was considered statistically significant.
Results
One hundred thirteen epileptic patients (48% male) between the age of 35.7 ± 14.9 (range 16-42 years) who were referred to the neurology clinic of KUMS were evaluated during the study period.
The mean age of epilepsy onset was 16.2 ± ± 10.6 years (range 1-36 years). Of the 113 patients, 46% had generalized tonic-clonic seizures, 38% complex partial, and 16% complex partial with secondary generalization. Twenty-five patients had one attack per week (22.1%), sixtytwo patients had one attack per month (54.9%) and twenty six patients had once in three months (23%).
After laboratory assessments, seven patients (4 males and 3 females) tested positive for the endomysial antibody (three patients had one attack per week and four patients had one attack per month). All of these IgA positive patients were also positive for CD in intestinal biopsies. Mean serum level of IgA in CD patients was 2.8 ± 1.1 µg/mL and in CD negative patients was 0.4 ± 0.2 µg/mL (p < 0.0001). After five months of instituting a gluten-free diet, seizure activity in six of seven patients was successfully controlled and anticonvulsant drugs were discontinued. Seizure activity in one case was controlled by half a dose of Carbamazepine (200 mg orally twice a day). Characteristics of epileptic patients with CD are shown in Table 1 .
Discussion
The relationship of CD and neurological complications has been observed during the past decades [8] . Neurological complications seen in patients with CD may be the prime presentation of this disease. Therefore, CD may easily go unrecognized and untreated.
Several studies have suggested an association between CD and epilepsy [10, 11] . The prevalence of celiac cases in people with epilepsy ranges from approximately 0.8-6% [8, 12] . In our study we found 7/113 patients (6%) diagnosed with CD, which is comparable with previous studies. Also, in Isfahan, Iran, Emami et al. found that 4 of 108 epileptic patients (3.7%) were positive for IgA anti t-TG [13] .
The mechanisms underlying the association between CD and epilepsy are unknown, but several mechanisms are suggested. CD is an immunemediated condition associated with sensitivity to a gluten diet. On the other hand, many immunological abnormalities have been labeled in patients with epilepsy. Studies have shown that epilepsy develops in several immune-mediated conditions such as SLE, myasthenia gravis and IgA deficiency [11, 14] Several immunoglobulin abnormalities which are described in patients with epilepsy, in part associated with anti-convulsant therapy, as well as a high prevalence of anticardiolipin and antinuclear antibodies have been seen in patients with epilepsy [11, 15] . Therefore, epilepsy in a number of patients may be due to an immune process, and the association between CD and epilepsy may be the susceptibility of immune-mediated conditions to occur together. Another suggested mechanism is that the antibodies related to CD may be themselves neurotoxic or may be a marker for a neurotoxic immunological process [6] .
Furthermore, several studies have demonstrated autoantibodies such as anti-tissue transglutaminase (TTG), antiendomysium and antireticulin in epileptic patients [13, 16, 17] . Calcium and magnesium deficiency, genetic factors and drug malabsorption, oxidative stress and free radical reposition were included in other elucidations [2, 18] .
According to these interpretations, there is a high suspicion that CD should be suspected in patients with epilepsy [11] . It is suggested that an epileptic patient with gastrointestinal symptoms, or with any evidence of malabsorption, should be tested for CD. Untreated CD may result in seizure control difficulty, through impaired drug absorption as well as nutrients and vitamins malabsorption [11] .
As expected, in the patients with CD who adhere to a gluten-free diet, seizure activity was better managed [7] . Delay in diagnosis of CD in epilepsy patients may adversely affect the overall outcome and result in unfavorable complications. It seems that early intervention with administration of combination of a gluten-free diet with anticonvulsant treatment is useful in patients with treatment-resistant epilepsy.
Previously, some studies suggested that glutenfree diet have a lucrative effect on seizure control [11, 19, 20] . In this study, we found that seizure activity successfully controlled in six of seven patients and in one patient anticonvulsant drugs reduced to half. In a small study by Hernandez et al. on four patients with epilepsy, bilateral occipital calcifications and latent CD, it was reported that three of four patients had significant reduction of seizure frequency after going on a gluten-free diet [20] . Also, a number of case studies have reported dramatic improvement in patients with refractory epileptic seizures that treated with a gluten-free diet plus antiepileptic therapy [16, 21] .
In conclusion, accumulating evidence suggests that CD is frequent in epileptic patients and it is suggested that epileptic patient with gastrointestinal symptoms are screened for CD. Administration of a combination of a gluten-free diet with anticonvulsant treatment is useful in patients with treatment-resistant epilepsy. 
